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Purpose. To investigate neovascular age-related macular degeneration (AMD) in patients aged ≥90 years from several
perspectives for a comprehensive overview: prevalence, presenting characteristics, treatment adherence, reasons for
discontinuation, and eﬃcacy of antivascular endothelial growth factor (VEGF) treatment comparing Ranibizumab and
Aﬂibercept. Methods. In this retrospective chart review, we determined the prevalence and presenting characteristics by
reviewing all data for patients referred to our department with treatment-naïve neovascular AMD. By looking at historical
cohorts, we determined adherence to treatment, reasons for discontinuation, and treatment outcomes after loading dose, 12
months, and 24 months. Results. Patients aged ≥90 years constituted 7% of the patients. Treatment was discontinued in
51%, primarily because of death and treatment burden. Mean change in best-corrected visual acuity was 3.2, 1.5, and −2.2
ETDRS letters at 4, 12, and 24 months, respectively. Aﬂibercept was superior to Ranibizumab in visual and anatomic
outcomes. After two years of treatment, patients losing ≥15 ETDRS letters made up 19% in the Aﬂibercept group and
26% in the Ranibizumab group. Conclusions. We propose that the very old patients with neovascular AMD may constitute
a distinctive group warranting special attention and possibilities for individualized therapy. Possible diﬀerences between
anti-VEGF agents need further investigations.
1. Introduction
Age-related macular degeneration (AMD) is the most
common reason for irreversible vision loss in the developed
world [1]. Neovascular AMD represents a late stage of the
disease, where vascular endothelial growth factor (VEGF)
mediated development of choroidal neovascularizations
(CNV) [2]. From only being able to postpone the inevitable
scarring of the macula and loss of central vision, we can
now improve or at least stabilize visual acuity and visual
function in the majority of patients by the widespread intro-
duction of anti-VEGF treatment [3–5].
Thepivotal phase 3 trialsMARINAandANCHORstudies
demonstrated that monthly Ranizbiumab (Lucentis, Novartis
International AG, Basel, Switzerland) improved mean visual
acuity for all subtypes of neovascular AMD [6, 7]. Its eﬃcacy
was later compared to that of Aﬂibercept (Eylea, Bayer AG,
Leverkusen, Germany) in the noninferiority VIEW trails,
where Aﬂibercept treatment was able to reach similar out-
comes [8].Aﬂibercept is similar toRanibizumab in itspharma-
codynamic properties but diﬀers in its pharmacokinetics due
to a VEGF-trap design that enables treatment with potentially
8 weeks’ intervals. Many clinical and observational studies
have conﬁrmed the eﬃcacy of Ranibizumab and Aﬂibercept
and explored the possibility individualizing therapy depend-
ing on the patient’s characteristics [9, 10]. One interesting
aspect is how anti-VEGF eﬃcacy is aﬀected by age. Several
studies ﬁnd that the change in best-corrected visual acuity
(BCVA) is negatively correlated with age [11–22]. Subgroup
analyses of the two years outcomes in the MARINA study
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found that unlike the younger patients which experienced a
signiﬁcant improvement of BCVA, patients ≥85 experienced
no change in BCVA [13]. Similar results were reported for
theﬁrst-year outcomes of theANCHORstudy [14]. Consider-
ing that anti-VEGF treatment experiences from daily clinical
practice can be somewhat less promising than that seen in
clinical trials [3], no change in BCVAmay be hard to achieve
in this patient group.
Ageing is an inevitable biological process that signiﬁ-
cantly aﬀects the cells and organs of the body. Macula
undergoes a range of changes [23]. The number of retinal
pigment epithelium (RPE) cells decreases while the number
of photoreceptors remains relatively stable [24]. Thus, each
RPE cell must support more photoreceptors, which increases
the metabolic and phagocytic stress on the RPE cells by
which they respond by increasing in size and becoming mul-
tinucleated [25]. These aged and stressed RPE cells develop a
higher VEGF response [26]. Taken together, increasing age
leads to increased fragility of the macula [23], which we
speculate may be a part of the reason for why the oldest
individuals experience worse treatment response.
The average life expectancy is 80 years in developed
countries such as Denmark, but diving into the statistics
reveals that although 60+ years old individuals constitute
25%—every fourth—of the population, only <1% reaches
90+ years of age [27]. These very old individuals (deﬁned as
having aged ≥90 years) represent a small group that may
signiﬁcantly diﬀer from the rest in terms of macular biology.
However, another important aspect is also their opinion on
the need for treatment and the burden of treatment in a
monthly/bimonthly treatment regime. In cancer research,
it is a well-documented phenomenon that some elderly
refuse treatment because the perceived gain life expectancy
does not outweigh the loss in quality of life [28]. Therefore,
there may be several aspects among the very old patients
with neovascular AMD with potential to inﬂuence the
treatment response.
In this study, we investigated neovascular AMD in
patients aged ≥90 years from several perspectives to give a
comprehensive overview. First, we looked at their overall
prevalence in a large tertiary retinal center and their present-
ing characteristics. Then, we looked at their adherence to anti-
VEGF treatment and reasons for discontinuation. Finally, we
evaluated results from anti-VEGF treatment and compared
eﬃcacy of Ranibizumab and Aﬂibercept using historical
cohorts where each was the primary choice of treatment.
2. Materials and Methods
2.1. Study Design and Patient Eligibility. This study is a
retrospective review of patients attending the Department
of Ophthalmology at Zealand University Hospital, Roskilde,
Denmark. All aspects of this study were conducted in accor-
dance with the ethical principles stated in the Declaration of
Helsinki. According to the national law and local hospital
research guidelines, no institutional review board approval
is required for retrospective observational clinical studies
that review routine clinical practice.
We ﬁrst determined the epidemiological aspects of
patients with neovascular AMD aged ≥90 years: the preva-
lence and their presenting characteristics. For this part of
the study, we reviewed all data for patients referred to our
department in the year 2014. Eligible for analyses were
patients with treatment-naïve neovascular AMD regardless
of the status of their lesion (i.e., whether or not it was deemed
treatable) or enrollment to anti-VEGF treatment. Diseases
that share features with neovascular AMD (e.g., polypoidal
choroidal vasculopathy) were not included.
Then, we looked at adherence to treatment, reasons for
discontinuation, and treatment outcomes for a 2-year period
comparing Aﬂibercept and Ranibizumab. For this part of the
study, we included treatment results from all our patients
aged ≥90 years diagnosed with treatment-naïve neovascular
AMD from 2009 to 2012 (where Ranibizumab was the pri-
mary choice of treatment) and from 2014 to 2015 (where
Aﬂibercept was the primary choice of treatment). In 2013
where Aﬂibercept was introduced in our clinic, we were con-
cerned about the ongoing discussions about Aﬂibercept
increasing the risk of cerebrovascular events [29] and allo-
cated patients with selected comorbidities to Ranibizumab
treatment. Hence, we did not include patients from 2013 to
avoid selection bias.
2.2. Access to Retinal Care. In Denmark, primary sector units
(practicing ophthalmologists and general practitioners) and
hospital departments refer all patients suspected of neovas-
cular AMD to ophthalmology departments since this is the
only access to free-of-charge anti-VEGF treatment. Within
1-2 workdays after receiving an electronic referral, the
patient is invited and booked for detailed retinal diagnosis.
From the time of booking, the patient is in most cases seen
within two weeks, depending on the patient’s availability
and the availability of the department. Patients are oﬀered
free-of-charge transportation between their home and the
hospital department, including patients that may need
wheelchair or special support.
2.3. Retinal Diagnosis.All patients referred for retinal diagno-
sis undergo a comprehensive ophthalmic examination
including dilated fundus examination, measurement of
best-corrected visual acuity (BCVA) in each eye using the
Early Treatment of Diabetic Retinopathy Study (ETDRS)
chart [30], retinal imaging using Heidelberg HRA-Spectralis
Spectral Domain optical coherence tomography (OCT) (Hei-
delberg Engineering, Heidelberg, Germany), and retinal
angiography using ﬂuorescein and indocyanine green. All
BCVAs were measured by personnel speciﬁcally trained in
ETDRS measurements. We used CC-100 charts (Topcon
Corp., Tokyo, Japan). All patients started from the top of
the chart and read each letter of each horizontal line and
progressed downwards until reaching a row where a mini-
mum of three letters on a line could not be read. Each eye
was tested individually and was scored according to correctly
identiﬁed number of letters. Patients read the chart at 4
meters (adding 45 letters to the ﬁnal score), but if the patient
was unable to read the letters, then the chart was read at 1
meter (adding 15 letters to the ﬁnal score).
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Treatment was initiated in eyes with neovascular AMD as
deﬁned in the Clinical Age-Related Maculopathy Staging
System (grade 5) [31] and in the presence of active CNV
and no predominance of ﬁbrosis and/or atrophy. In other
words, this included active subfoveal CNV as evaluated by
the presence of leakage in ﬂuorescence angiography with
the presence of one or more characteristics such as hemor-
rhage, exudates, serous detachments, and intraretinal edema.
If the BCVA was ≥20 ETDRS letters or the patient had
cardiovascular events within ≤3 months, treatment was
commenced on a case-by-case basis with special emphasis
on the state of the patient’s contralateral eye.
2.4. Treatment and Follow-Up. All eyes received three
consecutive monthly intravitreal injections with either
Aﬂibercept (0.05mL) or Ranibizumab (0.05mL). Choice of
Aﬂibercept or Ranibizumab was based on our local guide-
lines which were Ranibizumab prior to widescale Aﬂibercept
introduction in 2013 and Aﬂibercept as ﬁrst line of treatment
starting from 2014 based on national guidelines for the treat-
ment of neovascular AMD. Injections were given by physi-
cians or specially trained injection nurses [32]. After the
third injection, the patients were reevaluated in follow-ups
using dilated fundus examination, measurement of best-
corrected visual acuity (BCVA), and OCT scans to determine
whether or not the macula was dry so that additional injec-
tions may be warranted. The reevaluation was after 4 weeks
for Ranibizumab and 8 weeks for Aﬂibercept. We followed
a pro re nata (PRN) treatment regime for both Aﬂibercept
and Ranibizumab. Retreatment criteria, based on local guide-
lines and recommendations from the Danish Ophthalmolog-
ical Society, were the same during the study period (2009 to
2017) [33]: the presence of subretinal or intraretinal ﬂuid
on OCT or retinal hemorrhage either new or persisting. In
case of loss of visual acuity with no subretinal or intraretinal
ﬂuid, we repeated retinal angiography with ﬂuorescein and
indocyanine green to evaluate the presence of active CNV,
which was another retreatment criterion. In eyes with devel-
opment of untreatable retinal tubuli or ﬁbrotic scar, or
BCVA < 20 ETDRS letters with a dry macula, treatment
was stopped. If additional injections were needed, the patient
was booked for two to three anti-VEGF injections and ree-
valuated. Injections after the loading dose phase were given
with 4 weeks intervals for Ranibizumab and 8 weeks for
Aﬂibercept. If no additional injections were needed due to
a dry macula, we booked the patient for reevaluation. After
consecutive reevaluations with a dry macula, the disease
was considered provisionally inactive and the patient was
referred to a local primary sector ophthalmologist for
future controls.
2.5. Data Analysis and Statistics. The prevalence of patients
with neovascular AMD with an age≥ 90 was calculated
including a conﬁdence interval for the prevalence estimate
with a continuity correction [34]. We reviewed the identiﬁed
patients’ clinical characteristics using OCTs, angiographies,
and BCVA. BCVA was obtained from treatment databases.
Categorical variables are presented using numbers and
percentages and compared using the χ2-test and Fisher’s
exact test in case any subcategory had n < 5. Continuous var-
iables were checked for normal distribution using the
Kolmogorov-Smirnov test. Where normal distribution was
present, data was presented using mean and standard devia-
tion (SD) and tested using parametric tests. Age did not ﬁt
normal distribution and was right tailed, so this parameter
was presented in median and interquartile range (IQR) and
tested using Mann–Whitney U test.
Using data from eligible patients enrolled between 2009–
2012 and 2014-2015, we determined which patients discon-
tinued treatment and noted the reason. Based on diﬀerent
reasons for discontinuation, we explored adherence to treat-
ment over time using a time-to-event curve. We deﬁned the
start point as date of treatment start and followed the patient
until either event or censoring. Time-to-event curves were
made speciﬁcally for each reason for discontinuation by
censoring the other reasons.
Visual and anatomical treatment outcomes were
measured as change in BCVA and average central retinal
thickness (CRT) after approximately 4 months (ﬁrst reevau-
lation after treatment commencement), 12 months, and 24
months. The CRT was deﬁned as the average thickness of
an area with a diameter of 1mm around the fovea including
any subretinal hyperreﬂective material. Due to diﬀerent rea-
sons for treatment discontinuation, we analyzed data using
the last observation carried forward (LOCF) method to
account for missing data for all patients that had at least
one reevaluation after treatment commencement. LOCF
was not made for 24 months follow-up for patients started
in treatment in 2015 since most of these patients did not have
their follow-up at time of analysis (March 2017). We
assumed that using the LOCF on these patients would bias
the results towards better outcomes in the Aﬂibercept groups
because 12 months outcomes in general are better than 24
months outcomes.
When a patient’s both eyes were eligible for our analyses,
we only included data from one eye (the ﬁrst eye diagnosed
with neovascular AMD or the right eye in case both eyes were
diagnosed simultaneously) to avoid statistical problems with
assumptions of independent sampling. In the analyses, we
ﬁrst looked at whether the change in BCVA and average
CRT was signiﬁcant using a two-tailed one sample t-test
with a test value of 0. Changes in BCVA and average CRT
were then compared between patients receiving Aﬂibercept
with patients receiving Ranibizumab using a two-tailed inde-
pendent samples t-test. Eﬀect size was calculated using
Cohen’s d. Cohen deﬁned the following interpretation as a
rule of thumb: 0.2 small, 0.5 moderate, and 0.8 large [35].
Statistical analyses were made in SPSS version 23 (IBM,
Armonk, NY, USA). Figures were made using Prism 7
(GraphPad Software, La Jolla, CA, USA). P values below
0.05 were interpreted as sign of statistical signiﬁcance.
3. Results
3.1. Epidemiology: Prevalence and Presenting Characteristics.
A total of 282 patients with neovascular AMD were referred
to our clinic for retinal diagnosis during the year 2014.
Twenty of these patients were ≥90 years, corresponding to
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a prevalence of 7.1% (CI 95%: 4.5 to 10.9%). Age ranged from
90 to 99 years with median 92 years and IQR 90 to 95 years.
Eleven (55%) were females and nine (45%) males.
All patients presented with new neovascular AMD in one
eye only, and all patients presented with a macular condition
in the contralateral eye: early AMD in seven patients (35%),
geographic atrophy in ﬁve patients (25%), old ﬁbrotic AMD
in ﬁve patients (25%), macular hole in one patient (5%),
vitreomacular traction in one patient (5%), and subretinal
drusen in one patient (5%).
Mean BCVA was 48 ETDRS letters (SD: 15 ETDRS
letters). Average CRT was mean 454μm (SD: 125μm). Mean
lesion size was 3563μm (SD: 1081μm) measured using the
greatest linear dimension. Eleven eyes (55%) had predomi-
nantly classic lesion, seven eyes (35%) had predominantly
occult lesion, and two eyes (10%) had RAP. In 15 eyes
(75%), lesions were hemorrhagic in their appearance. All 20
patients were deemed eligible for treatment.
3.2. Treatment Adherence and Reasons for Discontinuation.
For this part of the study, we included treatment results from
all our patients aged ≥90 years diagnosed with treatment-
naïve neovascular AMD from 2009 to 2012 (where Ranibizu-
mab was the primary choice of treatment) and from 2014 to
2015 (where Aﬂibercept was the primary choice of treat-
ment) and which during the follow-up period of 2 years
was not switched from one anti-VEGF to another.
We identiﬁed a total of 116 patients treated with either
Aﬂibercept (n = 54) or Ranibizumab (n = 62). During the 2
years follow-up, 59 patients (51%) discontinued treatment.
Reasons for discontinuation are presented in Table 1 and
did not diﬀer signiﬁcantly depending on choice of anti-VEGF.
Using time-to-event analyses, we explored the impact of
each of these factors on the treatment adherence (Figure 1).
Death was an issue throughout the follow-up period. Patients
who did not wish to continue treatment due to the burden of
treatment made this choice within the ﬁrst year. Discontinu-
ation due to treatment results diﬀered: discontinuation due
to ﬁbrotic/untreatable lesions was more likely to happen after
the loading dose and within the ﬁrst year, whereas discontin-
uation due to inactive CNV/dry macula happened after the
ﬁrst year.
3.3. Visual and Anatomical Outcomes. Of the 116 patients
treated with either Aﬂibercept or Ranibizumab, 106 (91%)
remained in treatment for follow-up after the loading dose
phase. These patients were included for a comparison of
Aﬂibercept and Ranibizumab eﬃcacy in terms of visual and
anatomical outcomes. Patient characteristics are summarized
in Table 2 and were similar in terms of demographics, lesion
characteristics, and BCVA.
Overall, anti-VEGF therapy improved the BCVA at 4
months (after the loading dose phase) (mean change 3.2
(SD: 15.5) ETDRS letters, P = 0 036; one sample t-test) and
stabilized at 12 and 24 months (mean change 1.5 (SD: 16.5)
ETDRS letters, P = 0 342; mean change −2.2 (SD: 20.1)
ETDRS letters, P = 0 288; one sample t-test, resp., for 12 and
24 months). The average CRT decreased signiﬁcantly and
remained decreased at all follow-ups (mean change −130
(SD: 143) μm, P < 0 001; mean change −117 (SD: 150) μm,
P < 0 001; mean change −115 (SD: 158) μm, P < 0 001).
The mean number of treatments during 2 years was 5.7
(SD: 3.0). For Aﬂibercept and Ranibizumab, the mean
number of treatments was 5.6 (SD: 2.9) and 5.8 (SD: 3.1),
respectively. These numbers were inﬂuenced by 51% of
the patients discontinuing treatment during the follow-up.
Looking only at patients that continued treatment during
the 2 years, the overall mean number of treatments
increased to 7.2 (SD: 2.9). For Aﬂibercept and Ranibizumab,
these numbers increased to a mean of 6.7 (SD: 3.0) and 7.9
(SD: 2.9), respectively.
Aﬂibercept treatment signiﬁcantly improved BCVA at 4
months at mean 5.5 ETDRS letters (P = 0 014; one sample
t-test) (Table 3). Although there was a small improvement
at the later follow-ups at 12 and 24 months, its size was small
and did not reach statistical signiﬁcance (Table 3). The Δ
average CRT decreased signiﬁcantly at 4 months (P < 0 001;
one sample t-test) and remained signiﬁcantly decreased at
12 (P < 0 001; one sample t-test) and 24 months (P < 0 001;
one sample t-test) (Table 3).
Ranibizumab treatment was not associated with a signiﬁ-
cant improvement or worsening of BCVA at 4 months or 12
months but lead to a signiﬁcant decrease of 5.8 ETDRS letters
after 24 months (P = 0 028; one sample t-test) (Table 4). The
Δ average CRTdecreased signiﬁcantly at 4months (P < 0 001;
one sample t-test) and remained signiﬁcantly decreased at 12
(P < 0 001; one sample t-test) and 24 months (P < 0 001; one
sample t-test) (Table 4).
Overall, Aﬂibercept treatment was superior to Ranibizu-
mab treatment in ΔBCVA at all time points. However, the
mean diﬀerences between the groups were small initially and
did not reach statistical signiﬁcance until after 24 months:
after 4 months (4.4 (CI 95%: −1.6 to 10.3) ETDRS letters,
P = 0 149), after 12 months (4.5 (CI 95%: −1.9 to 10.8)
Table 1: Reasons for discontinuation of anti-VEGF treatment using either Aﬂibercept or Ranibizumab among patients with neovascular age-
related macular degeneration aged ≥90 years.
Aﬂibercept (n = 54) Ranibizumab (n = 62) P value
Death during follow-up, n (%) 7 (13) 9 (15) 0.809
Burdened by treatment/opted out of treatment, n (%) 6 (11) 10 (16) 0.434
Inactive CNV, dry macula, and referral of patient to the primary sector, n (%) 5 (9) 3 (5) 0.470
Treatment stopped due to development of a ﬁbrotic/untreatable lesion, n (%) 6 (11) 11 (18) 0.314
P values were calculated using the χ2-test for all categories, but inactive CNV, dry macula, and referral of patient to the primary sector was calculated using
Fisher’s exact test due to groups with <5.
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Table 2: Baseline factors of patients with neovascular age-related macular degeneration aged ≥90 years enrolled in Aﬂibercept or
Ranibizumab treatment, which remained in treatment for at least the follow-up after the loading dose phase.
Aﬂibercept (n = 49) Ranibizumab (n = 57) P value
Age, years, median (IQR) 91 (90 to 93) 91 (90 to 92) 0.400
Gender, n (%) 0.370
Female 35 (71) 45 (79)
Male 14 (29) 12 (21)
BCVA, ETDRS letters, mean (SD) 50 (14) 48 (18) 0.510
Average CRT, mean (SD) 433 (130) 445 (114) 0.660
Lesion type, n (%)† 0.309
Predominantly classic 16 (35) 18 (34)
Predominantly occult 25 (54) 34 (64)
Retinal angiomatous proliferation 5 (11) 1 (2)
IQR: interquartile range; SD: standard deviation; BCVA: best-corrected visual acuity; CRT: central retinal thickness.†No data on lesion type for three patients in
the Aﬂibercept group and four patients in the Ranibizumab group due to allergies to the contrast agents, lack of cooperation, or inaccessible data. P values were
calculated using the Mann–Whitney U test for age, χ2-test for gender, independent samples t-test for BCVA and average CRT, and Fisher’s exact test for lesion
type due to groups with <5.
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ETDRS letters, P = 0 164), and after 24 months (9.2 (0.8 to
17.5) ETDRS letters P = 0 031) (Figure 2). This corre-
sponded to Cohen’s d values of 0.3, 0.3, and 0.5, for 4, 12,
and 24 months, respectively, indicating an initially small
eﬀect size that grows to a moderate eﬀect size at 24 months.
We determined the rate of patients with loss of ≥15 ETDRS
letters in each group, which also showed that the diﬀerences
between the groups have a tendency of growing over time
(Figure 3). After 24 months, 19% in the Aﬂibercept group
had lost ≥15 ETDRS letters, whereas this number was 26%
in the Ranibizumab group.
The decrease in Δ average CRT was compared between
Aﬂibercept and Ranibizumab. Here, we saw a small but
nonsigniﬁcant more decrease among those treated with
Aﬂibercept group at all time points (34μm, 47μm, and
43μm, resp., for 4, 12, and 24, months) (Figure 4). These
changes corresponded to Cohen’s d values of 0.2, 0.3, and
0.3 for 4, 12, and 24 months, respectively, indicating a small
eﬀect size.
4. Discussion
Patients aged ≥90 years constitute 7% of patients with
neovascular AMD—approximately one out of every 14.
These patients have a high rate of treatment discontinuation,
where death and burden of treatment play a considerable
role. We also found that in these patients, Aﬂibercept therapy
was superior to Ranibizumab, although the eﬀect sizes were
only small to moderate. Diﬀerence between groups in the
CRT was small and not statistically signiﬁcant.
Diﬀerent aspects of anti-VEGF treatment may explain
our results. Klettner et al. investigated the eﬃcacy of Aﬂiber-
cept, Ranibizumab, and Bevacizumab in an experimental
setting using a RPE/choroid organ culture, where VEGF in
the supernatant was measured throughout 7 days and using
diﬀerent concentration of anti-VEGFs [36]. First, Aﬂibercept
required the lowest concentration for short-term VEGF inhi-
bition when compared to Ranibizumab and Bevacizumab
[36]. Second, one regular dose of Aﬂibercept inhibited VEGF
completely until the 7th day, whereas VEGF could be
detected after 72 hours with Ranibizumab treatment and
after 12 hours with Bevacizumab treatment [36]. Brinkmann
et al. compared the uptake of Aﬂibecept, Ranibizumab, and
Bevacizumab in vitro using ARPE-19 cell cultures, where
Aﬂibercept had signiﬁcantly faster uptake when compared
with Ranibizumab and Bevacizumab [37]. These ﬁndings
on cellular level may not necessarily have a clinical signiﬁcant
impact on a broader level as seen in the VIEW studies [8].
However, considering that RPE with age becomes more frag-
ile and develops a more potent VEGF response [23–26],
patients aged ≥90 years may constitute a group where the
aging process of RPE is at its utmost and where the pharma-
cokinetic diﬀerences between Aﬂibercept and Ranibizumab
give rise to clinically measureable diﬀerences. However, the
diﬀerences between Aﬂibercept and Ranibizumab on CRT
had a small eﬀect size in this study. It will be interesting to
see how anti-VEGF drugs with more potent pharmacokinetic
properties now in phase 3 trials, such as Abicipar/AGN-
150998 (Allergan, Irvine, CA, USA) and Brolucizumab/
RTH-258 (Novartis), will work on patients aged ≥90 years.
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Figure 2: Change in best-corrected visual acuity of eyes with
neovascular age-related macular degeneration in patients aged ≥90
years treated with either Aﬂibercept (red) or Ranibizumab (blue).
Dots and whiskers indicate mean and standard error.
Table 4: Two-year results on Ranibizumab treatment for neovascular
age-related macular degeneration in patients aged ≥90 years.
Ranibizumab (n = 57)
Mean (95% CI) P value
ΔBCVA, ETDRS letters
4 months 1.2 (−3.0 to 5.3) 0.570
12 months −0.5 (−4.8 to 3.7) 0.800
24 months −5.8 (−10.9 to −0.6) 0.028
Δ average CRT, μm
4 months −114 (−155 to −73) <0.001
12 months −95 (−138 to −52) <0.001
24 months −98 (−143 to −52) <0.001
BCVA: best-corrected visual acuity; CRT: central retinal thickness; CI:
conﬁdence interval. P values were calculated using the one sample t-test
with test value = 0.
Table 3: Two-year results on Aﬂibercept treatment for neovascular
age-related macular degeneration in patients aged ≥90 years.
Aﬂibercept (n = 49)
Mean (95% CI) P value
ΔBCVA, ETDRS letters
4 months 5.5 (1.1 to 9.9) 0.014
12 months 3.9 (−0.9 to 8.8) 0.106
24 months 3.4 (−3.4 to 10.2) 0.320
Δ average CRT, μm
4 months −148 (−185 to −111) <0.001
12 months −142 (−181 to −104) <0.001
24 months −141 (−185 to −97) <0.001
BCVA: best-corrected visual acuity; CRT: central retinal thickness; CI:
conﬁdence interval. P values were calculated using the one sample t-test
with test value = 0.
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Another explanation to our ﬁndings is that Aﬂibercept
allows eight weeks treatment intervals, which gives more
ﬂexibility from a clinical point-of-view. It is our experience
that ﬂexibility is much needed in the very old for a number
of practical reasons, such as localized infections around the
eye, systemic infections, fall trauma, or other conditions that
may shift the priorities and the focus of the patient. For such
cases, the eight weeks coverage of Aﬂibercept is less likely to
undertreat the patients compared with the four weeks cover-
age of Ranibizumab. Indeed, when looking at the number of
treatments, we only found that on average, ~1 additional
treatment was given with Ranibizumab, underscoring our
speculations of undertreatment of the Ranibizumab group.
We used a PRN regime, which some studies suggest may
be inferior to the treat and extend (T&E) regimen in terms of
visual outcomes [38]. In a systematic review and a network
meta-analysis, Danyliv et al. compared the two regimens
and found that although T&E was associated with better out-
comes compared to PRN, the eﬀect size was quite small and
clinically irrelevant: ~2 more ETDRS letters at 12 months
and 2-3 more ETDRS letters at 24 months [38]. This small
eﬀect size comes at a considerable cost: the T&E regimen is
associated with signiﬁcantly more injections [38]. However,
considering that the pharmacokinetic properties of anti-
VEGF drugs may play a larger role in patients aged ≥90 years,
which are in risk of undertreatment, there may also be a
potential for a larger gain using a T&E regime. Future studies
may shed light on these aspects.
A considerable number of our patients discontinued
treatment due to death or inacceptable burden of treatment.
These aspects reﬂect the speciﬁc diﬃculties when dealing
with patients aged ≥90 years [28]. In our study, we did not
ﬁnd any signiﬁcant diﬀerence between the Aﬂibercept and
Ranibizumab in the treatment discontinuation. We initially
speculated that a greater number of injections might lead to
a diﬀerence, but the number of injections between the groups
only diﬀered slightly. Details about burden of treatment
warrant further investigation as we might be able to
overcome any speciﬁc aspects proving to be an obstacle for
helping our patients; for example, it would be interesting to
know whether the perceived burden is due to speciﬁc factors
such as the injections or the frequent visits.
Although our health system is based on a free-of-charge
concept and even oﬀers free-of-charge transportation to
hospitals, actually utilizing that system may not be as
straightforward in this group of very old as in others. Some
of these patients informed that they did not seek help after
several months, which is particularly problematic since
timely treatment can be important factor for neovascular
AMD [39, 40]. It is hard to speculate whether these chal-
lenges reﬂect a generation issue in not wanting to burden
others, cognitive decline that are seen in among the very
old, or a concept of accepting that vision declines with age.
4 months 12 months 24 months 4 months 12 months 24 months
Aflibercept Ranibizumab
Lost 15 ETDRS letters:≥ 
Max loss<15 ETDRS letters:
8% 12% 19%
92% 88% 81%
9% 16% 26%
91% 84% 74%
Figure 3: Rate of patients with neovascular age-related macular degeneration aged ≥90 years that experience a loss of ≥15 ETDRS letters in
best-corrected visual acuity during treatment with either Aﬂibercept (red) or Ranibizumab (blue).
50
‒100
‒150
‒200
0
0 4 12 24
(휇
m
)
Months since treatment starts
훥 average CRT
Figure 4: Change in average central retinal thickness of eyes with
neovascular age-related macular degeneration in patients aged ≥90
years treated with either Aﬂibercept (red) or Ranibizumab (blue).
Dots and whiskers indicate mean and standard error.
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Interesting exploratory studies may provide better insight
into the future.
Limitations should be noted when interpreting our
results. This was retrospective observational study where
historic cohorts were compared. Although we tried to mini-
mize selection bias by not including participants from 2013,
where Ranibizumab was used on patients with cardiovascular
comorbidities; a better study design would include a random-
ized allocation of patients to Aﬂibercept and Ranibizumab.
We used LOCF handle missing data due to treatment discon-
tinuation, and in that regard, it should be noted that a consid-
erable number of our patients discontinued treatment for
diﬀerent reasons. However, we do not suspect that this
results in skewed data between Aﬂibercept and Ranibizumab
since the groups did not diﬀer in treatment discontinuation.
Finally, it should be noted that the mean diﬀerence between
Aﬂibercept and Ranibizumab was at ~2 ETDRS lines at most,
and as a rule of thumb, a clinically signiﬁcant diﬀerence is 3
ETDRS lines [41].
5. Conclusion
Patients aged ≥90 years constitute a small but important
proportion of those referred for treatment of neovascular
AMD. These very old patients have a high rate of treatment
discontinuation, where death and burden of treatment play
a considerable role. Although both Aﬂibercept and Ranibizu-
mab decreased the average CRT, Aﬂibercept seemed superior
to Ranibizumab in terms of change in BCVA after the load-
ing dose and after 12 and 24 months in patients aged ≥90
years. Important reasons may be pharmacokinetic diﬀer-
ences between the two drugs or the relative more ﬂexibility
of treatment every 8 weeks versus 4 weeks with Aﬂibercept
versus Ranibizumab; however, studies with prospective and
randomized design are needed for more conclusive results.
We propose that the very old patients constitute a distinctive
group that may warrant special attention.
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